Form 4 for KURA Kura Oncology, Inc.
Accepted 2026-05-20 16:05:22 ET · period of report 2026-05-19 · accession 0001193125-26-232547 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-05-20 16:05 | 2026-05-19 | KURA | Powl Brian T. | Chief Commercial Off | S - Sale | $9.21 | -339 | 183.6K | -0.2% | -$3,122 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-19 | S | D | 339 | $9.21 | 183,614 | D | — | — | (F1) The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2025. (F2) 678 shares were acquired on May 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan. |